The global CAR-T cell therapy market for multiple myeloma is witnessing rapid growth, with the United States emerging as the clear leader. In 2025 and 2026, the U.S. is expected to dominate this market due to advanced healthcare infrastructure, regulatory approvals, and significant investments in innovative cancer treatments.

---

Market Size and Growth Projections

In 2024, the CAR-T cell therapy market for multiple myeloma was valued at USD 3.4 billion. By 2033, it is projected to reach USD 12.6 billion, growing at a CAGR of 15.8% from 2026 to 2033.

The broader global CAR-T cell therapy market is also set for expansion, with estimates showing growth from USD 8.46 billion in 2025 to USD 88.51 billion by 2034, at a CAGR of 29.8%.

---

Key Market Drivers

1. United States’ Advanced Healthcare Ecosystem

The U.S. boasts an advanced healthcare infrastructure and robust clinical research network, positioning it as the top country for CAR-T cell therapy development and adoption.

2. Regulatory Support

In 2025, the FDA removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved CAR-T therapies. This change has streamlined access for healthcare providers and patients.

3. Rising Multiple Myeloma Cases

Over 32,000 new cases of multiple myeloma are diagnosed annually in the United States alone, driving demand for cutting-edge treatments.

4. Technological Innovation

Advancements in CAR-T cell engineering are enhancing efficacy and safety, attracting investment from both pharmaceutical giants and biotech startups.

---

Leading Therapies and Clinical Developments

Approved Therapies in the U.S.

Abecma (idecabtagene vicleucel): Bristol Myers Squibb’s BCMA-directed therapy is approved for relapsed/refractory multiple myeloma.

Carvykti (ciltacabtagene autoleucel): Johnson & Johnson and Legend Biotech’s CAR-T therapy has demonstrated a 45% reduction in mortality risk over three years.

Emerging U.S. Therapies

Anito-cel: Gilead Sciences and Arcellx’s candidate achieved a 97% response rate in clinical trials, with 62% of patients showing complete responses.

---

Regional Market Insights

United States – The Global Leader

The U.S. leads the CAR-T cell therapy market thanks to FDA approvals, research investments, and partnerships between major pharmaceutical companies and biotech innovators.

Asia-Pacific – The Fastest Growing Region

Countries like China and Japan are catching up with increasing healthcare investments and clinical trials.

---

Future Outlook

With robust clinical pipelines and regulatory support, the U.S. CAR-T cell therapy market for multiple myeloma will remain dominant through 2025 and 2026. Other regions are expected to follow suit as access to these therapies expands globally.

---

Sources

• CAR T-Cell Therapies Market Size Skyrockets 29.8% CAGR by 2034 – Towards Healthcare

• CAR T-Cell Therapy for Multiple Myeloma Market | 2025-2033 – Market Growth Reports

• CAR T-Cell Therapy for Multiple Myeloma Market’s Strategic Roadmap – Data Insights Market

• Legend Biotech: J&J-Tied Cancer Drug Cuts Risk Of Death By 45% – Investors.com

• Arcellx and Legend Bio Trade Jabs in Multiple Myeloma – Investors.com